Literature DB >> 1693166

Monoclonal antibodies to three structural proteins of Newcastle disease virus: biological characterization with particular reference to the conformational change of envelope glycoproteins associated with proteolytic cleavage.

Y Umino1, T Kohama, T A Sato, A Sugiura, H D Klenk, R Rott.   

Abstract

Monoclonal antibodies (MAbs) to the haemagglutinin-neuraminidase (HN), fusion (F) and matrix (M) proteins of Newcastle disease virus were prepared and characterized. At least three non-overlapping or partially overlapping antigenic sites were delineated on the HN, three on the F and three on the M proteins by competitive binding assays. Antigenic sites on the HN and F proteins roughly represented functional domains defined by serological tests. Two antigenic sites on the F protein were involved in virus neutralizing and haemolysis-inhibiting activity. These antigenic determinants were readily affected by treatment with certain surfactants and acetone. Proteolytic cleavage of the HN and F proteins was associated with conformational change, revealed by altered reactivity with MAbs and by altered topological arrangements of some epitopes. None of the anti-M MAbs inhibited any biological activities of the virus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1693166     DOI: 10.1099/0022-1317-71-5-1189

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  11 in total

1.  Pathotyping of Newcastle disease viruses by RT-PCR and restriction enzyme analysis.

Authors:  T Nanthakumar; R S Kataria; A K Tiwari; G Butchaiah; J M Kataria
Journal:  Vet Res Commun       Date:  2000-05       Impact factor: 2.459

2.  The 3D structure of the fusion primed Sendai F-protein determined by electron cryomicroscopy.

Authors:  Kai Ludwig; Bolormaa Baljinnyam; Andreas Herrmann; Christoph Böttcher
Journal:  EMBO J       Date:  2003-08-01       Impact factor: 11.598

3.  Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein.

Authors:  Hsien-Sheng Yin; Reay G Paterson; Xiaolin Wen; Robert A Lamb; Theodore S Jardetzky
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-17       Impact factor: 11.205

4.  Two domains that control prefusion stability and transport competence of the measles virus fusion protein.

Authors:  Joshua Doyle; Andrew Prussia; Laura K White; Aiming Sun; Dennis C Liotta; James P Snyder; Richard W Compans; Richard K Plemper
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Role of the simian virus 5 fusion protein N-terminal coiled-coil domain in folding and promotion of membrane fusion.

Authors:  Dava S West; Michael S Sheehan; Patrick K Segeleon; Rebecca Ellis Dutch
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

6.  Hemagglutinin-neuraminidase-independent fusion activity of simian virus 5 fusion (F) protein: difference in conformation between fusogenic and nonfusogenic F proteins on the cell surface.

Authors:  M Tsurudome; M Ito; M Nishio; M Kawano; H Komada; Y Ito
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

7.  Conserved glycine residues in the fusion peptide of the paramyxovirus fusion protein regulate activation of the native state.

Authors:  Charles J Russell; Theodore S Jardetzky; Robert A Lamb
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

8.  Generation of monoclonal antibodies specific of the postfusion conformation of the Pneumovirinae fusion (F) protein.

Authors:  Laura Rodríguez; Eduardo Olmedillas; Vicente Mas; Mónica Vázquez; Olga Cano; María C Terrón; Daniel Luque; Concepción Palomo; José A Melero
Journal:  J Virol Methods       Date:  2015-08-12       Impact factor: 2.014

Review 9.  Next-generation direct-acting influenza therapeutics.

Authors:  Mart Toots; Richard K Plemper
Journal:  Transl Res       Date:  2020-02-04       Impact factor: 7.012

10.  More than one component of the Newcastle disease virus particle is capable of interferon induction.

Authors:  K Wertz; M Büttner; A Mayr; O R Kaaden
Journal:  Vet Microbiol       Date:  1994-04       Impact factor: 3.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.